end-of-life care may involve discontinuation of drugs, except for palliative drug therapy (eg, strong analgesics, steroids, and anxiolytics). Women with EOC are therefore prone to polypharmacy of varying magnitude during the course of the disease and with relation to the prognosis.
Polypharmacy is associated with an increased risk of adverse drug interactions and events, 4 which may affect the quality of care in women with EOC. Further, polypharmacy and discontinuation of concomitant drugs pose substantial challenges for pharmacoepidemiological research aimed at evaluating potential associations with cancer risk or prognosis of commonly used drugs for chronic conditions, eg, aspirin, statins, or metformin, as changes in adherence to these drugs may directly or indirectly influence cancer risk or outcomes.
A comprehensive assessment of drug therapy among EOC patients would provide important guidance for future clinical practice, safety, prognosis, and quality of life for these women, and provide important information for pharmacoepidemiological studies of EOC prognosis. Presently, however, only limited knowledge is available on prevalence, trends, and factors associated with drug use among EOC patients. We therefore aimed to describe drug utilization among postmenopausal women with EOC, with focus on temporal patterns in drug use and consideration of tumor characteristics and clinical stage.
| MATERIAL AND ME THODS
We obtained data from nationwide Danish health and demographic registries on all women with postmenopausal EOC. Using descriptive statistics, we examined use of prescription drugs preceding and following the EOC diagnosis.
| Data sources
The nationwide Danish registries hold information for the entire population on demographic parameters and health data, including cancer incidence and use of prescription drugs. Unambiguous linkage between registries can be accomplished using the CPRnumber, a unique personal identifier assigned by the Danish Civil Registration System to all residents in Denmark. 5 The Danish Civil Registration System contains information on date of birth and dates of migration and death for all Danish citizens. 5 In the present study, we also obtained data from the Danish Cancer Registry, 6 the Danish National Prescription Registry, 7 Discharge/contact diagnoses are coded according to ICD-8 (1977 ICD-8 ( -1993 ) and ICD-10 (since 1994).
| Patient population
We included all women aged ≥ 55 years diagnosed with histologically verified EOC between 2005 and 2012. Women with previous cancer (except non-melanoma skin cancer) were excluded. All patients were followed from 3 years before the EOC diagnosis until date of death, migration, or 3 years after the diagnosis. For each patient using risk set sampling, we randomly selected four women (controls) without cancer at the date of diagnosis of the patient from the general female population with same birth year as the case patients, thereby establishing a cancer-free comparison cohort.
| Study drugs
We considered drug treatment at the fourth level of the ATC system, corresponding to drug classes, eg, proton-pump inhibitors (ATC A02BC). Prescriptions for antibiotics (ATC J01) were excluded from analysis, as antibiotic therapy is rarely chronic. New (incident) drug treatment was defined as a prescription within a specific drug class, filled by a patient with no previous prescription within the same drug class for the preceding 2 years.
| Statistical analyses
In analyses of both new and total drug use, we evaluated drug use from 36 months before to 36 months after the date of EOC diagnosis. First, we described the overall incidence rate of treatment initiation with prescription drugs over time within the population of EOC patients. Specifically, we estimated the monthly incidence rate of new drug treatment per 100 persons per 'person-month'. Similar analyses were performed for the cancer-free comparison cohort. We further described total use of prescription drugs by estimating the
Key Message
Drug use among postmenopausal patients with epithelial ovarian cancer is substantial, with the rate of new drug treatments increased 3-5 months before diagnosis. Only limited changes were seen after diagnosis in use of preventive medicines.
total number of unique drug classes used by each patient/control woman within 3-month exposure windows, depicting the distribution of number of drugs used over time (median, 25th and 75th centile, and 10th and 90th centiles).
Second, we described overall trends in exposure to the most commonly used drugs around the time of diagnosis. Specifically, we identified the most used drug classes during the first 6 months after diagnosis and described the proportion of patients using these drugs in 6-month intervals. In this analysis, drug use in each time-interval was defined as at least one prescription within the time-interval.
In secondary analyses, we repeated the analyses stratified by histological type of epithelial cancer (serous, endometrioid, clear cell, and mucinous) and by tumor stage (localized, nonlocalized, unknown).
All analyses were performed using STATA Release 14.2 (StataCorp, College Station, TX, USA).
| Ethical approval
The Danish Health Data Authority approved the study (approval 2015-57-0008). According to Danish law, ethical approval is not required for registry-based studies. 10 
| RE SULTS
We identified 4119 women with EOC between 2005 and 2012.
After exclusions [post-mortem diagnosis (n = 38), non-epithelial/ no histology (n = 338), age < 55 years (n = 760), and previous cancer (n = 241)], the final study population comprised 2742 patients with incident EOC. The median age was 69 years (interquartile range 62-76 years). The majority of patients had serous EOC (59.5%) and about one-half (49.2%) had verified non-localized disease at the time of diagnosis (Table 1 ).
The analysis of initiation of new drug treatment ( Figure 1) showed an increase from 3-5 months before the time of diagnosis, peaking at 99 new drug treatments per 100 individuals during the first month after the diagnosis. Compared with the control women, EOC patients had a consistently higher rate of new drug treatment, which persisted up to 3 years after the diagnosis ( Figure S1 ).
In post-hoc exploratory analysis, we identified the most common drug classes driving this increase in new drug therapy among the EOC patients, defined as new drugs initiated in the period from 3 months before the diagnosis to 6 months after the diagnosis (ie, corresponding to the peak observed in Figure 1 ). This analysis
showed that a wide range of drugs contributed, with antiemetics, proton-pump inhibitors, hypnotics, and opioids being the most common ( Table 2 ).
The number of drug classes used by the EOC patients increased in the period immediately following the diagnosis (Figure 2 ). While the median use only increased slightly, a more noticeably increase was seen for the 75th and 90th percentiles of drug users.
The analysis of overall exposure trends of the most commonly used drug classes (top 20 listed in Table 3 ) showed a marked increase in the use of specific drug classes, including antiemetics and proton-pump inhibitors (in line with the above findings). Most of the drug classes that displayed a peak immediately after the time of diagnosis, however, declined somewhat during the subsequent time intervals. As an example, the prevalence of proton-pump inhibitor use increased from 10% 2 years before diagnosis to 30%
immediately after the diagnosis and fell to 24% 2 years after the diagnosis. Similar trends were seen for, eg, antiemetics (1%, 20%, and 7%), opioids (2%, 17%, and 10%), and benzodiazepine-related A table similar to Table 3 , but with data from 36 months before to 36 months after the diagnosis, and the 50 most commonly used drugs (instead of 20) is provided in Table S1 .
Of note, use of hormone replacement therapy showed a marked decrease from 17% in the 6 months before the diagnosis to 8%
in the 6 months after the diagnosis, and increasing to about 12% thereafter (Table S1 ).
Secondary analyses stratified by histological type revealed results similar to those of the main analysis, ie, a peak around the time of diagnosis for a number of drugs and a subsequent decline to levels somewhat higher than those before the diagnosis (Table S2A- 
| D ISCUSS I ON
In our nationwide study, we have documented a substantial use of An important strength of our study was the nationwide approach, minimizing selection bias and misclassification, and the use of highquality registry data on cancer incidence 6 and prescription drug use. 7 Some limitations, however, also need to be considered. The primary weakness of our study was the lack of data on complementary and TA B L E 2 Drug classes initiated among epithelial ovarian cancer patients between 3 months before and 6 months after the diagnosis, corresponding to the period of highest incidence rate of new drug treatment. The official WHO name is used, with specification provided in parentheses.
alternative medicines reported to be used by a considerable proportion of patients with cancer, [11] [12] [13] as well as over-the-counter medication, which is also frequently used. 14, 15 Another limitation was the lack of data on the reasons for discontinuation of drug treatment. Although our staging information allowed some assessment of trends associated with prognosis, more specific proxies such as data on which patients entered palliative care would have allowed for more detailed analyses. Further, we did not have access to prescriber data, ie, whether drug therapy was initiated or managed in primary care or by hospital physicians. Lastly, our analyses did not incorporate data on diagnoses, ie, the underlying reasons for drug treatment. ications. This is in full accordance with previous studies on end-of-life drug use, both among patients with advanced cancer disease 18 and among patients with limited life expectancy in general. 19 One specific and increasingly recognized issue is the risk of drug-drug interactions, which is of particular concern among cancer patients due to the typical narrow therapeutic index of chemotherapeutic agents. 20, 21 Examples of drug-drug interactions with chemotherapeutic agents used in EOC therapy include the interaction between antidepressant drugs and platin-based chemotherapy 22 and the increased toxicity observed among patients receiving paclitaxel with a concomitant use of the common antiplatelet drug clopidogrel. 23, 24 However, drug-drug interactions are not the only concern associated with polypharmacy among patients with cancer, as drug-related adverse events are both more common 4 and more often of higher severity among cancer patients compared with other patients.
25
Our findings also have some important implications for pharmacoepidemiological studies on women with EOC and cancer patients in general. First, the markedly increased use of drugs leading up to the date of the EOC diagnosis infers a risk of reverse causation bias (protopathic bias) in cancer risk studies, ie, that drug use assessed close to the diagnosis may be erroneously associated with an increased cancer risk, when in fact the drug use was caused by an as yet undiagnosed cancer. However, as shown in our previous study, 26 an average lag-time of 6 months seems sufficient to avoid such bias.
Studies on cancer prognosis is another increasingly common but inherently difficult 27-29 pharmacoepidemiological discipline. As illustrated by our study, drug use around the time of an EOC diagnosis cannot be perceived as a random event. Rather, new drug use after the diagnosis is, for the majority, closely related to cancer symptoms and use of preventive medicines around and after the cancer diagnosis is governed by increased medical surveillance, prediagnosis comorbidity, and, to some extent, cancer prognosis. As such, comparison of cancer survival among users vs nonusers of a certain drug after the EOC diagnosis may be confounded by (the typically incompletely assessed) baseline prognosis, and careful evaluation of the influence of temporal exposure patterns in relation to the time of diagnosis on the studied association is warranted.
The distribution of number of different drug classes used per woman in 6-month intervals (median, 25th and 75th centile, and 10th and 90th centiles) within 12 months before to 12 months after epithelial ovarian cancer diagnosis (black) and among age-matched cancer-free women (gray)
TA B L E 3 Use of the 20 most commonly used prescription drugs, defined by their prevalence of use in the 6-month period immediately after diagnosis, in 6-month intervals from 24 months before to 24 months after epithelial ovarian cancer diagnosis. Sorted by ATC code 
| CON CLUS ION
We have shown that drug use is frequent among postmenopausal women with EOC, with a considerable increase of new drug therapy around the time of the cancer diagnosis but only limited changes in the use of preventive medicines following the EOC diagnosis.
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